Sionna Therapeutics (SION) Long-Term Investments (2024 - 2026)

Quarterly results put Long-Term Investments at $73.8 million for Q1 2026, down 13.2% from a year ago — trailing twelve months through Mar 2026 was $73.8 million (down 13.2% YoY), and the annual figure for FY2025 was $74.4 million, up 262.94%.

Sionna Therapeutics has reported Long-Term Investments over the past 3 years, most recently at $73.8 million for Q1 2026.

  • Long-Term Investments reached $73.8 million in Q1 2026 per SION's latest filing, down from $74.4 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $85.0 million in Q1 2025 and bottomed at $20.5 million in Q4 2024.
  • Median Long-Term Investments over the past 3 years was $74.6 million (2025), compared with a mean of $67.5 million.
  • The largest annual shift saw Long-Term Investments soared 262.94% in 2025 before it decreased 13.2% in 2026.
  • Over 3 years, Long-Term Investments stood at $20.5 million in 2024, then skyrocketed by 262.94% to $74.4 million in 2025, then fell by 0.86% to $73.8 million in 2026.
  • Business Quant data shows Long-Term Investments for SION at $73.8 million in Q1 2026, $74.4 million in Q4 2025, and $76.7 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - 505,194.89
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 5.75 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 9.79 Bn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 22.17 Mn
10 Sionna Therapeutics 1.87 Bn 1.87 Bn - 73.78 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 73.78 Mn
Dec 31, 2025 74.42 Mn
Sep 30, 2025 76.67 Mn
Jun 30, 2025 74.70 Mn
Mar 31, 2025 85.00 Mn
Dec 31, 2024 20.51 Mn